Icecure Medical

IceCure Medical secured regulatory approval from China's National Medical Products Administration for its ProSense cryoablation system and associated cryoprobes, a Class III medical device clearance that allows the technology to be commercially marketed in China. The approval adds China to the list of major markets where ProSense can be commercialized, alongside existing clearances across the United States, Europe and Asia, and broadens IceCure's addressable market by opening access to one of the world's largest healthcare markets. ProSense is IceCure's flagship liquid-nitrogen-based cryoablation system, designed to destroy tumors by freezing them as a minimally invasive alternative to surgical removal, and is primarily focused on breast, kidney, bone and lung cancer applications. Management said the approval reinforces the company's global regulatory standing and advances efforts to expand patient access to minimally invasive tumor treatment options. Shares of ICCM lost approximately 4% in after-market trading following the announcement and have plunged 88.3% year to date, against the industry's 1.9% growth, while the company currently has a market capitalization of $7.2 million. The clearance follows a recent exclusive distribution agreement with Scovas Medical to commercialize ProSense in the Netherlands for breast cancer and interventional oncology applications.

IceCure Medical reported approximately 45% revenue growth in Q2 2026, driven by increased system sales and disposable probe utilization. The company's U.S. commercial footprint expanded by about 70% following FDA clearance for early-stage low-risk breast cancer, and gross margin improved to 30% despite unfavorable foreign exchange fluctuations. Management expects to enroll the first patients in the CHOICE study within 3 to 4 weeks and remains on track to meet the FDA-mandated hurdle of 80 patients treated by March 2027. The company completed a financing round in the second quarter, raising approximately $8.5 million in gross profit to strengthen the balance sheet.

IceCure Medical announced expanding commercial adoption of its ProSense cryoablation system in Brazil, following FDA marketing authorization for early-stage, low-risk breast cancer. The minimally invasive system, which destroys tumors by freezing, already holds ANVISA approval in Brazil and is being used across breast, lung, kidney, and musculoskeletal cancers. Two independent trials are underway: a 750-patient study led by Dr. Vanessa Sanvido in Brazil and a 900-patient study led by Dr. Toulsie Ramtohul of the Institut Curie in France, both comparing cryoablation outcomes with standard care. At the SOBRICE Onco 2026 congress in São Paulo, leading experts presented clinical experiences with ProSense, highlighting its growing role in interventional oncology. CEO Eyal Shamir noted that FDA clearance has boosted awareness and physician interest in Brazil, positioning ProSense as a versatile solution for multiple tumor types.

IceCure Medical has regained compliance with Nasdaq's minimum bid price requirement. The company received written notice from Nasdaq on June 18, 2026, confirming that its ordinary shares maintained a closing bid price of at least $1.00 per share for 10 consecutive business days from June 4 to June 17, 2026. Nasdaq now considers the bid price deficiency matter closed.

IceCure Medical highlighted a newly published peer-reviewed journal article demonstrating key clinical advantages of its ProSense cryoablation over radiofrequency ablation for early-stage breast cancer. The article, published in the International Journal of Surgery, which is ranked third globally among surgical journals, was authored by leading Japanese breast cancer specialists and reports that thermal ablation technologies have shown local tumor control rates comparable to breast-conserving surgery for appropriately selected patients with small breast tumors, while offering shorter procedures, minimal scarring, and improved cosmetic outcomes. The publication notes that cryoablation can be performed under local anesthesia, unlike radiofrequency ablation which requires general anesthesia, and allows flexible adjustment of the ice ball size with visible margins, whereas radiofrequency ablation is harder to control. IceCure is preparing for the 34th Annual Meeting of the Japanese Breast Cancer Society in Kyoto on June 25-27, 2026, and its exclusive distributor in Japan, Terumo Corporation, one of the world's top 20 medical device companies, is expected to submit ProSense for regulatory approval in breast cancer to Japan's Pharmaceuticals and Medical Devices Agency in the second half of 2026.

Several biotechnology companies reported significant regulatory, clinical, and commercial developments this week. NeOnc Technologies Holdings received Investigational New Drug authorization from the Department of Health – Abu Dhabi for NEO212, its oral brain tumor therapy, marking the first international regulatory clearance for the program. uniQure announced that the FDA indicated its Phase I/II data could support a Biologics License Application for accelerated approval of AMT-130 in Huntington's disease, with submission planned for the third quarter of 2026. IceCure Medical reported a 70% increase in its active U.S. commercial install base for the ProSense breast cancer cryoablation platform since receiving FDA clearance in October 2025. ClearPoint Neuro expanded its brain drug delivery ambitions through a 10-year focused ultrasound development partnership with Sungkyunkwan University in South Korea.